Dr. Philip Kantoff and Dr. Lauren Harshman led a study that found hormone-sensitive prostate cancer patients who started on cholesterol-lowering statin drugs at initiation of androgen-deprivation therapy experienced a longer time to disease progression.
Dr. Philip Kantoff commented on prostate cancer screening and treatment
Dr. Christopher Sweeney discussed the future of prostate cancer research.
Dr. Paul Nguyen led a study looking at the link between certain prostate cancer treatments and heart-related deaths.
Steven Chang led a study showing robotic surgery for
prostate cancer may have led to changes in the number of surgeons performing
prostate removals and in the overall cost.
Paul L. Nguyen led a study showing prostate cancer patients with health
insurance are less likely to have metastatic disease or die from the
cancer than those without health insurance.
Dr. Mary-Ellen Taplin commented on a study showing that lung, liver, and other gut metastases are associated with the poorest survival in advanced hormone-refractory prostate cancer.
Tags: chemotherapy, ProstateCancer
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: